Quest Diagnostics Inc vs Emerson Electric Co. — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while Emerson Electric Co. trades at $136.3 (market cap $76.22B). The key difference: Emerson Electric Co. is far larger — about 3.3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | EMR | |
|---|---|---|
Market Cap | $22.80B | $76.22B |
Sector | Health | Industrials |
52-Week High | $216.02 | $161.69 |
52-Week Low | $166.42 | $123.30 |
Enterprise Value | $28.82B | $88.49B |
Dividend Yield | 1.67% | 1.63% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Emerson Electric (EMR) trades at $135.38, down 2.52% on the day, with a bearish technical signal and mixed earnings history. The stock shows moderate valuation ratios (P/E 31.34, P/S 4.17) and stable profitability (net margin 13.35%). Recent news highlights upcoming Q3 2026 earnings and dividend activity, while cash flow trends indicate operational strength but net outflows.
The outlook is cautiously optimistic with a consensus price target of $157.60 (16.4% upside), supported by analyst buy ratings (51.2%). Key risks include volatile cash flows and competitive pressures in manufacturing electronics. Earnings growth and sector momentum remain catalysts for potential appreciation.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →